I'll take a stab and guess not only will the earnings be announced before the market opens, but given that NVS is a European corporation, it will be announced even before the European markets open.
NVS probably won’t give investors the generic-Lovenox sales number directly, but investors may be able to ballpark the number by the degree to which NVS ascribes an increase in the guidance for 2010 year-over-year parent-company sales to the contribution from Lovenox.
It’s also possible that NVS won’t have anything to say about Lovenox other than a general statement that the launch is proceeding according to plan.